[Opioids in patients with renal impairment]

Area of Science:

• Pharmacology
• Nephrology
• Pain Management

Background:

• Renal impairment affects drug elimination, increasing risks of opioid accumulation and toxicity.
• Understanding opioid pharmacokinetics is crucial for safe prescribing in patients with kidney disease.

Purpose of the Study:

• To review renal elimination processes of opioids.
• To discuss pharmacokinetic properties of various opioids.
• To provide clinical practice recommendations for opioid use in renal impairment.

Main Methods:

• Review of literature on opioid pharmacokinetics and renal elimination.
• Analysis of opioid properties relevant to patients with reduced kidney function.
• Formulation of evidence-based clinical guidelines.

Main Results:

• Fentanyl, alfentanil, and buprenorphine are suitable for patients with renal impairment due to favorable pharmacokinetics.
• Codeine and pethidine are contraindicated in renal impairment.
• Morphine use is restricted (creatinine clearance < 30 ml/min), with hydromorphone as an alternative.
• Methadone, oxycodone, and tramadol require cautious use with dose reduction.

Conclusions:

• Opioid selection and dosing must be individualized based on renal function.
• Specific opioids pose higher risks in renal impairment and necessitate avoidance or careful monitoring.
• Clinical guidelines aid in optimizing opioid therapy for patients with kidney disease.